Pancreatic Cancer Research

ResearcherUniversity of VeronaActive in the last 2 years

Matteo Fassan

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6515-5482; OpenAlex author ID A5046301295. Sources: OpenAlex.

Their work

Papers
17 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
100
Papers, trials and grants by year

2014: 2 papers · 2015: 1 paper · 2016: 4 papers · 2017: none · 2018: none · 2019: 1 paper · 2020: none · 2021: 1 paper · 2022: 1 paper · 2023: 4 papers · 2024: none · 2025: 1 paper · 2026: 2 papers

Papers 17

  1. High fidelity of Claudin-18.2 expression in primary and matched metastatic (lymph nodes, peritoneum, and liver) pancreatic ductal adenocarcinoma: a foundation … Co-author DOI 10.1016/j.humpath.2025.106014↗
  2. Morphologic Characterization of Pancreatic Ductal Adenocarcinoma following Post-neoadjuvant Pancreatectomy and Clinical Value of Intratumor Heterogeneity. Co-author DOI 10.1097/sla.0000000000006565↗
  3. Claudin-18.2 immunohistochemical evaluation in pancreatic cancer specimens: review and recommendations for routine testing and scoring. Last author DOI 10.1007/s00428-025-04222-2↗
  4. Clinical and Genomic Characterization of Pancreatic Ductal Adenocarcinoma with Signet-Ring/Poorly Cohesive Cells. Co-author DOI 10.1016/j.modpat.2023.100251↗
  5. Establishment of a human 3D pancreatic adenocarcinoma model based on a patient-derived extracellular matrix scaffold. Co-author DOI 10.1016/j.trsl.2022.08.015↗
  6. Extrahepatic Distal Cholangiocarcinoma vs. Pancreatic Ductal Adenocarcinoma: Histology and Molecular Profiling for Differential Diagnosis and Treatment. Co-author DOI 10.3390/cancers15051454↗
  7. Role of Immune Microenvironment in Pancreatic Ductal Adenocarcinoma: Could It Be Considered a Predictor of Prognosis? Co-author DOI 10.3390/curroncol30060417↗
  8. Interrupting the nitrosative stress fuels tumor-specific cytotoxic T lymphocytes in pancreatic cancer. Co-author DOI 10.1136/jitc-2021-003549↗
  9. Modulation of pancreatic cancer cell sensitivity to FOLFIRINOX through microRNA-mediated regulation of DNA damage. Co-author DOI 10.1038/s41467-021-27099-6↗
  10. MAP Kinase inhibition reshapes tumor microenvironment of mouse pancreatic cancer by depleting anti-inflammatory macrophages Co-author DOI 10.1101/759779↗
  11. Expression of DRD2 Is Increased in Human Pancreatic Ductal Adenocarcinoma and Inhibitors Slow Tumor Growth in Mice. Co-author DOI 10.1053/j.gastro.2016.08.040↗
  12. The pattern of hMENA isoforms is regulated by TGF-β1 in pancreatic cancer and may predict patient outcome. Co-author DOI 10.1080/2162402x.2016.1221556↗
  13. RASSF1 tumor suppressor gene in pancreatic ductal adenocarcinoma: correlation of expression, chromosomal status and epigenetic changes. Co-author DOI 10.1186/s12885-016-2048-0↗
  14. miR-21 expression and clinical outcome in locally advanced pancreatic cancer: exploratory analysis of the pancreatic cancer Erbitux, radiotherapy and UFT (PERU… Co-author DOI 10.18632/oncotarget.7208↗
  15. Pancreatic ductal adenocarcinoma cell lines display a plastic ability to bi‑directionally convert into cancer stem cells. Co-author DOI 10.3892/ijo.2014.2796↗
  16. Key role of dual specificity kinase TTK in proliferation and survival of pancreatic cancer cells. Co-author DOI 10.1038/bjc.2014.460↗
  17. Inflammation and pancreatic cancer: molecular and functional interactions between S100A8, S100A9, NT-S100A8 and TGFβ1. Co-author DOI 10.1186/1478-811x-12-20↗

Closest collaborators

The 25 strongest of 100 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Aldo Scarpa · 12 shared papers, 2014–2026 · strength 1.27
  2. Claudio Luchini · 6 shared papers, 2016–2026 · strength 1.11
  3. Roberto Salvia · 4 shared papers, 2022–2026 · strength 0.73
  4. Giuseppe Malleo · 4 shared papers, 2016–2026 · strength 0.68
  5. Rita Teresa Lawlor · 5 shared papers, 2016–2026 · strength 0.61
  6. Paola Mattiolo · 2 shared papers, 2026 · strength 0.50
  7. Carlotta Franzina · 2 shared papers, 2026 · strength 0.50
  8. Salvatore Paiella · 3 shared papers, 2022–2026 · strength 0.46
  9. Antonio Pea · 2 shared papers, 2023–2026 · strength 0.36
  10. Michele Simbolo · 3 shared papers, 2019–2023 · strength 0.35
  11. Michèle Milella · 3 shared papers, 2016–2023 · strength 0.32
  12. Vincenzo Corbo · 3 shared papers, 2019–2023 · strength 0.30
  13. Sara Lonardi · 2 shared papers, 2023 · strength 0.28
  14. Αναστάσιος Γκουντάκος · 2 shared papers, 2023 · strength 0.28
  15. Nicola Silvestris · 2 shared papers, 2023 · strength 0.28
  16. Manabu Takamatsu · 1 shared paper, 2025 · strength 0.27
  17. Teri A. Longacre · 1 shared paper, 2025 · strength 0.27
  18. Matteo De Pastena · 1 shared paper, 2026 · strength 0.24
  19. Fabio Casciani · 1 shared paper, 2026 · strength 0.24
  20. Alessandro Esposito · 1 shared paper, 2026 · strength 0.24
  21. Gabriella Lionetto · 1 shared paper, 2026 · strength 0.24
  22. Massimo Donadelli · 1 shared paper, 2026 · strength 0.24
  23. Vincenzo Bronte · 2 shared papers, 2019–2022 · strength 0.17
  24. Francesco De Sanctis · 2 shared papers, 2019–2022 · strength 0.17
  25. Marco Agostini · 1 shared paper, 2023 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.